Immunicum AB: Immunicum Appoints Leopold Bertea as Chief Technology Officer
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, announced the appointment of Leopold Bertea, PhD, as Chief Technology Officer (CTO), effective as of today, May 5, 2022. In his role as CTO at Immunicum, Dr. Bertea will be driving the build-up of a global manufacturing infrastructure for Immunicum’s lead pipeline program, DCP-001, which is currently progressing through a Phase II clinical study. Additionally, he will oversee the process development to further optimize the manufacturing of the company’s current and future products and the building out of the company’s process development facilities and capabilities in Leiden, The Netherlands.
Dr. Bertea joins Immunicum from Cellectis, a clinical-stage biotechnology company using a proprietary gene-editing platform to develop cell and gene therapies, where he most recently held the position of Senior Vice President Technical Operations Europe and Member of the Cellectis Executive Committee. With previous senior roles at Novartis, LFB Biotechnologies and LFB’s subsidiary CELLforCURE, Sanofi, and Ciba-Geigy, Dr. Bertea brings a total of 27 years biopharmaceutical industry experience to Immunicum.
During his tenure with LFB Biotechnologies and CELLforCURE, Dr. Bertea was instrumental as President and CEO of CELLforCURE for establishing the manufacturing plant and CDMO operations at the Les Ulis site, near Paris, as one of the first and largest production units for cell and gene therapies in Europe at that time. Following the acquisition of CELLforCURE by Novartis in 2019, Dr. Bertea became General Manager and Site Head of the new Novartis’ site in Les Ulis, which was successfully refocused under his supervision for manufacturing the autologous cell and gene therapy Kymriah® (tisagenlecleucel), as well as new cell and gene therapy pipeline projects of Novartis. Dr. Bertea holds a Ph.D. in Chemical Engineering from ETH Zurich.
“Dr. Bertea brings an impressive track record in biopharmaceutical process development and production, including commercial-scale manufacturing to Immunicum. He joins the Company at a crucial stage, as we are continuing to build out our in-house process development activities in our new R&D facilities in Leiden and preparing for the next stage of development for DCP-001 and ilixadencel”, commented Erik Manting, PhD, Chief Executive Officer of Immunicum.
“Immunicum’s expertise in allogeneic dendritic cell biology has delivered a promising pipeline of novel, off-the-shelf cancer immunotherapy candidates combining competitive clinical efficacy with a benign safety profile. I’m exciting to leverage my expertise in cell and gene therapy development and manufacturing to support the next development phases for the company’s lead assets and its wider pipeline”, commented Leopold Bertea, PhD, Chief Technology Officer of Immunicum.
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Executive Officer
Stern Investor Relations
Telephone: +1 212-362-1200
Telephone: +49 160 9352 9951
ABOUT IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for blood-borne and solid tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sinch resolves on an in-kind issue of shares to the sellers of Pathwire26.5.2022 10:00:00 CEST | Press release
Stockholm, Sweden – 26 May 2022 – Sinch AB (publ) (the “Company” or “Sinch”), a global leader in cloud communications for mobile customer engagement, today announces that the board of directors, in accordance with what was communicated on 7 December 2021, has resolved on an in-kind share issue of 25.5 million shares to the sellers of Pathwire. On 30 September 2021, Sinch disclosed that it had entered into an agreement to acquire Pathwire and the acquisition was completed on 7 December 2021. In addition to the cash consideration, Sinch shall issue an aggregate of 51 million shares in the Company as consideration to the sellers, of which the first 25.5 million shares were issued in February 2022. The board of directors has today resolved to issue the remaining 25.5 million of these shares. The payment of the shares consists of a receivable, under the agreement for the acquisition of Pathwire, against two of the company’s subsidiaries. The contributed receivable amounts to the remaining U
Sinch beslutar om apportemission av aktier till säljarna av Pathwire26.5.2022 10:00:00 CEST | Pressemelding
Stockholm, Sverige – 26 maj 2022 – Sinch AB (publ) (”Bolaget” eller ”Sinch”), en ledande global leverantör av molntjänster för kundinteraktion via mobilen, meddelar idag att styrelsen, i enlighet med vad som har kommunicerats i pressmeddelande den 7 december 2021, har beslutat om apportemission av 25,5 miljoner aktier till säljarna av Pathwire. Sinch offentliggjorde den 30 september 2021 att avtal om att förvärva Pathwire hade ingåtts och förvärvet slutfördes den 7 december 2021. I tillägg till den kontanta köpeskillingen ska Sinch emittera sammanlagt 51 miljoner nya aktier i Sinch som del av vederlaget till säljarna, varav de första 25,5 miljoner aktierna emitterades i februari 2022. Styrelsen har idag beslutat att emittera de resterande 25,5 miljoner aktierna. Betalningen har skett genom apport av en fordran enligt avtalet avseende förvärvet av Pathwire, på två av Bolagets dotterbolag, om de återstående 500 miljoner USD (den initiala delen av fordran om 500 miljoner USD tillfördes i
Nokia and Taiwan Mobile strengthen partnership with energy-efficient 5G coverage expansion deal26.5.2022 07:00:00 CEST | Press release
Press Release Nokia and Taiwan Mobile strengthen partnership with energy-efficient 5G coverage expansion deal New deal will see delivery of enhanced country-wide 5G coverage; Nokia’s energy-efficient AirScale portfolio will support TWM’s sustainability commitments Expansion of 5G Standalone Core includes slicing and low-latency edge cloud for enterprise, and Voice over New Radio (VoNR) 26 May 2022 Espoo, Finland – Nokia today announced that it has been selected by Taiwan Mobile (TWM) in an expansion deal to enhance the operator’s 5G coverage across the country. Under the deal, Nokia will provide its latest energy-efficient AirScale portfolio supporting TWM’s commitments to RE100 and reaching 100 percent renewable energy by 2040. It will also provide a smooth network evolution path following the completion of the proposed merger with Taiwan Star. Nokia will provide equipment from its AirScale portfolio, including base stations and massive MIMO antennas to boost network performance and c
Mandalay Resources Corporation Announces the Results of Its Annual General Meeting of Shareholders25.5.2022 23:32:49 CEST | Press release
TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce the results of its Annual General Meeting of Shareholders (the “Meeting”) held today virtually. All the resolutions presented at the Meeting were approved by the shareholders, with the votes cast by proxy representing 67.63% of the total shares outstanding as of the record date. Election of Directors The number of directors was fixed at seven members and each of the seven nominees listed in the Company’s Management Information Circular dated April 14, 2022, were re-elected to the Company’s Board of Directors. Abraham Jonker remains the lead independent director and Bradford Mills continues as Chair. Results of the votes cast by proxy are set out below. ResolutionVotes Cast by Proxy For% ForVotes Cast by Proxy Withheld% WithheldBradford A. Mills61,552,12099.95329,1930.047Abraham Jonker61,551,31399.95130,0000.049Amy Freedman61,547,53899.94
Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress25.5.2022 22:01:00 CEST | Press release
Celebrating EULAR’s 75thanniversary with focus on a new era of rheumatoid arthritis care Mechelen, Belgium;25 May 2022, 22.01CET;Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark. The broad range of abstracts include trial data analyses supporting the efficacy and safety profile of filgotinib andreal-world clinical data around alignment of prescribing between physicians and rheumatoid arthritis (RA) patients. Galapagos is also hosting a hybrid symposium: “Evolving patient care in RA: Can JAK inhibitors meet patient and physician expectations for RA treatment?”, which will include a discussion focused on aligning physician and patient treatment goals, looking at what is meant by ‘comprehensive care’ and how to ensure that people living with RA are part of treatment and care goal setting. A meet-the-expert session, “Patient-centred care in RA: cutting through th